Atopic Dermatitis

This analysis highlights the efficacy and safety of abrocitinib among patients with atopic dermatitis in China, as well as the medication’s impact on patients’ blood biomarkers.

Infants who develop atopic dermatitis show early cheek skin barrier dysfunction with delayed FLG processing, low ceramides, and high IL-18. The study will be presented at AAAAI 2025.

Children with severe atopic dermatitis saw > 5 percentile height gains after 16 weeks of dupilumab, per a study to be presented at AAAAI 2025.

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

Our top 5 headlines include a trial of gene-edited pig kidneys, a first-of-its-kind antibiotic approval, and new guidelines for migraine.

These data suggest that the Family Acceptance and Commitment Therapy-based Eczema Management Program, or FACT-EMP, may be helpful to children with atopic dermatitis.

These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.

In this analysis, investigators concluded that dupilumab may be a viable treatment choice for pregnant or breastfeeding mothers with atopic dermatitis.

These data suggest a wearable haptic feedback sensor powered by artificial intelligence may function as a supportive therapeutic device for those with atopic dermatitis.

These new data were announced by LEO Pharma following the phase 3 DELTA TEEN trial, assessing delgocitinib 20mg/g cream for chronic hand eczema (CHE).

This study highlights upadacitinib’s efficacy across clinical phenotypes for those with atopic dermatitis, noting any differences in response rates among patients.

Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such as Eczema Area and Severity Index (EASI)-75/90, Investigator Global Assessment (IGA), and itch scores alongside patient-reported outcomes to guide decisions while also considering disease severity and the impact of atopic comorbidities in treatment approaches

These findings highlight dupilumab’s use as a potential treatment option for individuals with prurigo nodularis.

The findings in this analysis indicate that a balanced, infrequent diet including proteins and fats may provide individuals with a potential strategy for management of atopic dermatitis.

Panelists discuss the diagnosis and referral process for patients with pediatric atopic dermatitis (AD) from both the dermatologist and allergy perspectives, including when a child should be referred to a dermatologist and the importance of a multidisciplinary approach to care for optimizing AD management, with insights on the roles each team member plays in patient care.

Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.

The results of this analysis point to the significance of emotions in the treatment and functional outcomes of those with dandruff.

In this observational cross-sectional study, investigators highlighted the challenges associated with tapering cortisone creams for patients with atopic dermatitis.

These real-life data highlight dupilumab’s efficacy at 16 weeks, with the safety and effectiveness in children with atopic dermatitis continuing to 52 weeks.

This systematic review and meta-analysis highlighted several key findings on use of probiotics as a treatment of pediatric patients with allergies to food.

In this analysis, the investigators sought to assess the ability of a ChatGPT-4-based chatbot in its performance of key functions in a teledermatology platform.

These data highlight current applications of AI and machine learning in aesthetic medicine, looking specifically at studies graded as Level I or II.

Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.

This analysis highlights the transcriptomic patterns of chronic hand eczema, indicating the potential of novel drug targets.

New topline data released by Inmagene indicate positive findings from a phase 2a trial on IMG-007 for moderate-to-severe atopic dermatitis.

This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.